FR08C0046I1 - IN VITRO RECONSTRUCTION OF SEGMENTED POLARITY-NEGATIVE RNA VIRUSES - Google Patents

IN VITRO RECONSTRUCTION OF SEGMENTED POLARITY-NEGATIVE RNA VIRUSES

Info

Publication number
FR08C0046I1
FR08C0046I1 FR08C0046C FR08C0046I1 FR 08C0046 I1 FR08C0046 I1 FR 08C0046I1 FR 08C0046 C FR08C0046 C FR 08C0046C FR 08C0046 I1 FR08C0046 I1 FR 08C0046I1
Authority
FR
France
Prior art keywords
segmented
polarity
rna viruses
negative rna
vitro reconstruction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0046(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916794.2A external-priority patent/GB9916794D0/en
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of FR08C0046I1 publication Critical patent/FR08C0046I1/en
Application granted granted Critical
Publication of FR08C0046I2 publication Critical patent/FR08C0046I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

There is disclosed a method for generating in cultured cells infectious viral particles of a segmented negative-strand virus by an entirely vector-based system without the aid of a helper virus. The method may, for example, be particularly useful for producing modified influenza viruses.
FR08C0046C 1999-07-14 2008-11-13 IN VITRO RECONSTRUCTION OF SEGMENTED POLARITY-NEGATIVE RNA VIRUSES Active FR08C0046I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14364599P 1999-07-14 1999-07-14
GBGB9916794.2A GB9916794D0 (en) 1999-07-16 1999-07-16 In vitro virus reconstitution
PCT/GB2000/002710 WO2001004333A1 (en) 1999-07-14 2000-07-14 In vitro reconstitution of segmented negative-strand rna viruses

Publications (2)

Publication Number Publication Date
FR08C0046I1 true FR08C0046I1 (en) 2009-01-02
FR08C0046I2 FR08C0046I2 (en) 2011-11-25

Family

ID=26315773

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0046C Active FR08C0046I2 (en) 1999-07-14 2008-11-13 IN VITRO RECONSTRUCTION OF SEGMENTED POLARITY-NEGATIVE RNA VIRUSES

Country Status (12)

Country Link
EP (1) EP1194580B2 (en)
AT (1) ATE353370T1 (en)
AU (1) AU5998400A (en)
CA (1) CA2379012C (en)
CY (2) CY1106404T1 (en)
DE (5) DE122007000061I2 (en)
DK (1) DK1194580T4 (en)
ES (1) ES2278621T5 (en)
FR (1) FR08C0046I2 (en)
LU (1) LU91367I2 (en)
NL (4) NL300294I2 (en)
WO (1) WO2001004333A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1086207T3 (en) 1998-06-12 2007-05-29 Sinai School Medicine New methods and inteferon-deficient substrates for the propagation of viruses
WO2002083896A2 (en) * 2001-04-17 2002-10-24 Institut Pasteur Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
HUE050222T2 (en) 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Signal for packaging of influenza virus vectors
FR2866031B1 (en) * 2004-02-11 2012-10-19 David Francois Joseph Millet EMERGING PATHOGENIC VIRUS CHIMER, MEDICAMENT CONTAINING THE SAME, AND USE IN ANTIVIRAL THERAPY
CA2559371C (en) 2004-03-09 2014-07-08 Chiron Corporation Influenza virus vaccines
BRPI0511776B1 (en) 2004-06-01 2016-11-29 Sinai School Medicine genetically engineered swine influenza attenuated virus, immunogenic formulation, pharmaceutical formulation, use of the immunogenic formulation, use of genetically engineered swine influenza attenuated virus, use of the pharmaceutical formulation and method for producing a vaccine, an immunogenic formulation or a pharmaceutical formulation
AU2005318087B2 (en) 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
KR20080025171A (en) 2005-06-21 2008-03-19 메드이뮨 백신즈 인코포레이티드 Methods and compositions for expressing a heterologous protease
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102727885A (en) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
JP2009514839A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Adjuvant influenza vaccine containing cytokine inducer
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
DK2368572T3 (en) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvant vaccines with non-virion antigens produced from influenza viruses grown in cell culture
WO2007052061A2 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
US9387242B2 (en) 2005-12-02 2016-07-12 Icahn School Of Medicine At Mount Sinai Chimeric viruses presenting non-native surface proteins and uses thereof
WO2007085969A2 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (en) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー Preserving influenza vaccines that are not refrigerated
JP5491173B2 (en) * 2006-04-19 2014-05-14 メディミューン，エルエルシー Methods and compositions for expressing minus-strand viral RNA in canine cells
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008147496A2 (en) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Neuraminidase-deficient live influenza vaccines
WO2008156681A2 (en) * 2007-06-14 2008-12-24 Yoshihiro Kawaoka Adenoviral vectors for influenza virus production
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
EP2045323A1 (en) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP2233568A1 (en) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Novel method for generation of RNA virus
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
PL2396032T3 (en) 2009-02-10 2017-05-31 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
JP5845180B2 (en) 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ Influenza viruses and their use
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
JP2013526849A (en) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ Influenza virus vaccine and use thereof
US20130183740A1 (en) 2010-06-02 2013-07-18 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
ES2655051T3 (en) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Influenza virus with mutant PB2 gene segment as live attenuated vaccines
SG11201400743VA (en) 2011-09-20 2014-04-28 Sinai School Medicine Influenza virus vaccines and uses thereof
CA2852857A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP2708552A1 (en) 2012-09-12 2014-03-19 Medizinische Universität Wien Influenza virus
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
BR112015017420A2 (en) * 2013-01-23 2017-07-11 Novartis Ag influenza virus recombination
US20140274806A1 (en) 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR102407019B1 (en) 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 Combination method for treatment of cancer
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CL2014003146A1 (en) * 2014-11-20 2015-06-12 Univ Santiago Chile Method to produce negative single stranded arn virus; functional recombinant plasmid in animal cells, consisting of a pss-urg skeleton; method of obtaining viral particles; and use to express arn, autogenous or exogenous proteins to the virus.
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
JP2018524323A (en) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド Antigen matched influenza vaccine
US10416171B2 (en) 2015-07-07 2019-09-17 Seqirus UK Limited Influenza potency assays
JP2018530314A (en) 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション Generation of infectious influenza virus from virus-like particles
JP7237344B2 (en) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus hemagglutinin protein and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
CN113874496A (en) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) Humanized cell lines
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
CN111363727B (en) * 2020-01-20 2021-09-24 武汉大学 Recombinant influenza virus carrying helicobacter pylori, host cell, preparation method and application thereof
EP3896077A1 (en) 2020-04-16 2021-10-20 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Influenza virus-like particles (vlps)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
EP1820853B1 (en) * 1999-04-06 2011-09-21 Wisconsin Alumni Research Foundation Recombinant influenza viruses for vaccines and gene therapy

Also Published As

Publication number Publication date
DE122007000061I2 (en) 2011-07-21
DE122007000061I1 (en) 2007-12-20
ES2278621T5 (en) 2011-02-02
NL300294I1 (en) 2007-12-03
DE60033284D1 (en) 2007-03-22
DE60033284T2 (en) 2007-10-25
FR08C0046I2 (en) 2011-11-25
DE60033284T3 (en) 2014-10-30
EP1194580A1 (en) 2002-04-10
NL300301I2 (en) 2008-10-01
NL300369I1 (en) 2009-01-05
CA2379012C (en) 2013-07-02
DE122007000070I1 (en) 2008-01-31
CA2379012A1 (en) 2001-01-18
NL300301I1 (en) 2008-01-02
DK1194580T4 (en) 2011-01-03
WO2001004333A1 (en) 2001-01-18
EP1194580B1 (en) 2007-02-07
DE122008000057I1 (en) 2009-04-09
DK1194580T3 (en) 2007-04-10
CY2007023I1 (en) 2009-11-04
CY2007023I2 (en) 2009-11-04
DE122008000056I1 (en) 2009-04-09
NL300368I1 (en) 2009-01-05
NL300368I2 (en) 2017-08-03
NL300294I2 (en) 2008-10-01
EP1194580B2 (en) 2010-08-25
LU91367I2 (en) 2007-11-21
CY1106404T1 (en) 2010-07-28
AU5998400A (en) 2001-01-30
ATE353370T1 (en) 2007-02-15
ES2278621T3 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
FR08C0046I2 (en) IN VITRO RECONSTRUCTION OF SEGMENTED POLARITY-NEGATIVE RNA VIRUSES
CY1110964T1 (en) METHOD OF PRODUCING LARGE-SCALE VACCINES
CA2401117A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
CA2205015A1 (en) Method for producing biologicals in protein-free culture
DK1108787T3 (en) Preparation of vaccines
BRPI0407636A (en) cell culture medium, animal cell lineage, methods for producing a conditioned culture medium, animal cells, an animal cell culture, virus in an animal cell culture, or preferably anchor-dependent diploid human, method for produce a vaccine, and virus population
FR07C0012I2 (en) METHOD FOR IN VITRO DISASSEMBLY-REASSEMBLY OF VIROID PARTICLES (VLP) OF PAPILLOMAVIRUS
DE69626022D1 (en) METHOD FOR THE INDUSTRIAL PRODUCTION OF A JAPANESE ENKEPHALITIS VACCINE, AND Vaccine Obtained In This Way
WO2003049767A3 (en) Method of large scale production of hepatitis a virus
BRPI0002694B8 (en) process of obtaining vero cell rabies vaccine for human use
TH58373B (en) Enhanced immunogens For vaccines that are not stimulated to fight infectious diseases caused by the Genes family. Ensifalitis virus And a method to produce that